Prostanoid receptors and the urogenital tract

Current Opinion in Investigational Drugs

Volumn 4, Issue 11, 2003, Pages 1343-1353

  Breyer, Matthew D ^a   Hébert, Richard L ^b   Breyer, Richard M ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cyclooxygenase; Dinoprost; Dinoprostone; Fertility; Kidney; Prostacyclin

Indexed keywords

11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; ARACHIDONIC ACID; BUTAPROST; CYCLOOXYGENASE 2 INHIBITOR; FLUPROSTENOL; G PROTEIN COUPLED RECEPTOR; GR 63799; MISOPROSTOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ONO 8815LY; ONO AE 1259; ONO AE 1329; ONO AE 248; ONO DI 004; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1 RECEPTOR; PROSTAGLANDIN E3 RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN F2 ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROSTANOID RECEPTOR; SC 51322; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; BLADDER EPITHELIUM; BLADDER FUNCTION; CHILDBIRTH; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG STRUCTURE; EDEMA; EPITHELIUM; FEMALE GENITAL SYSTEM; FERTILITY; GLOMERULUS; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPORENINEMIA; INHIBITION KINETICS; INTERSTITIAL CYSTITIS; KIDNEY; KIDNEY DISEASE; MALE GENITAL SYSTEM; NEUROMUSCULAR FUNCTION; NONHUMAN; OVARY; PREMATURE LABOR; PROSTATE; PROTEIN LOCALIZATION; REPRODUCTION; REVIEW; SIDE EFFECT; SODIUM EXCRETION; SODIUM RETENTION; TESTIS; UROGENITAL SYSTEM; UTERUS; VAS DEFERENS;

ANIMALS; HUMANS; MOLECULAR STRUCTURE; PROSTAGLANDINS, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; UROGENITAL SYSTEM;

EID: 0345832385     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Bergström S: Prostaglandins: Members of a new hormonal system. These physiologically very potent compounds of ubiquitous occurrence are formed from essential fatty acids. Science (1967) 157(787):382-391.
2. Bergström S, Carlson LA, Weeks JR: The prostaglandins: A family of biologically active lipids. Pharmacol Rev (1968) 20(1):1-48.
3. Oliw E: Prostaglandins and kidney function. An experimental study in the rabbit. Acta Physiol Scand (1979) 461:1-55.
4. Dunn MJ, Hood VL: Prostaglandins and the kidney. Am J Physiol (1977) 233(3):169-184.
5. Bonvalet JP, Pradelles P, Farman N: Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 253(3 Pt 2):F377-F387.
6. DeWitt DL, Smith WL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA (1988) 85(5):1412-1416.
7. Smith WL, Langenbach R: Why there are two cyclooxygenase isozymes. J Clin Invest (2001) 107(12):1491-1495.
8. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA (1992) 89(16):7384-7388.
9. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem (1991) 266(20):12866-12872.
10. O'Banion MK, Winn VD, Young DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA (1992) 89(11):4888-4892.
11. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem (2000) 69:145-182.
12. Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: Structures, properties, and functions. Physiol Rev (1999) 79(4):1193-1226.
13. Tsuboi K, Sugimoto Y, Ichikawa A: Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat (2002) 68-69:535-556. Comprehensive review of the roles and functions of the prostanoid receptors.
14. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD: Prostanoid receptors: Subtypes and signaling. Annu Rev Pharmacol Toxicol (2001) 41:661-690.
15. Aoki J, Katoh H, Yasui H, Yamaguchi Y, Nakamura K, Hasegawa H, Ichikawa A, Negishi M: Signal transduction pathway regulating prostaglandin EP3 receptor-induced neurite retraction: Requirement for two different tyrosine kinases. Biochem J (1999) 340(2):365-369.
16. Katoh H, Negishi M, Ichikawa A: Prostaglandin E receptor EP3 subtype induces neurite retraction via small GTPase Rho. J Biol Chem (1996) 271(47):29780-29784.
17. Fujino H, Srinivasan D, Regan JW: Cellular conditioning and activation of β-catenin siganling by the FPB prostanoid receptor. J Biol Chem (2002) 277(50):48786-48795.
18. 2. J Biol Chem (2002) 277(4):2614-2619.
19. 4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem (2003) 278(14):12151-12156.
20. Breyer MD, Harris RC: Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens (2001) 10(1):89-98. Overview of renal effects of NSAIDs and coxibs.
21. Breyer MD, Breyer RM: G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol (2001) 63:579-605. An in-depth review of renal prostanoid receptor function.
22. Harris RC: Cyclooxygenase-2 in the kidney. J Am Soc Nephrol (2000) 11(12):2387-2394.
23. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M et al.: The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta (2000) 1483(2):285-293. A detailed description of the ligand affinities of human prostanoid receptors.
24. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in chinese hamster ovary cells. Br J Pharmacol (1997) 122(2):217-224. A detailed description of the ligand affinities of mouse prostanoid receptors.
25. Breyer MD, Breyer RM: Prostaglandin E receptors and the kidney. Am J Physiol Renal Physiol (2000) 279(1):F12-F23.
26. 2 receptor. Nature (1991) 349(6310):617-620.
27. 2 receptor: cDNA cloning, expression and Northern blot analysis. Biochem Biophys Res Commun (1992) 184(3):1197-1203.
28. Abe T, Takeuchi K, Takahashi N, Tsutsumi E, Taniyama Y, Abe K: Rat kidney thromboxane receptor: Molecular cloning signal transduction and intrarenal expression localization. J Clin Invest (1995) 96(2):657-664.
29. 2 receptor gene. Biochem Biophys Res Commun (1999) 256(2):391-397.
30. 2 in the mouse kidney. Am J Physiol (1996) 271(6 Pt 2):F1131-F1138.
31. 2. J Clin Invest (1998) 102(11):1994-2001.
32. 2 receptor expression and TGF response to U-46,619. Am J Physiol (1997) 373(6 Pt 2):F976-F983.
33. Welch WJ, Wilcox CS: Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic. Role of macula densa. J Clin Invest (1992) 89(6):1857-1865.
34. Wilkes BM, Solomon J, Maita M, Mento PF: Charactetization of glomerular thromboxane receptor sites in the rat. Am J Physiol (1989) 256 (6 Pt 2):F1111-F1116.
35. Spurney RF, Fan PY, Ruiz P, Sanfilippo F, Pisetsky DS, Coffman TM: Chronic thromboxane receptor blockade reduces renal injury in murine lupus nephritis. Kidney Int (1992) 41(4):973-982.
36. Spurney RF, Onorato JJ, Albers FJ, Coffman TM: Thromboxane binding and siganl transduction in rat glomerular mesangial cells. Am J Physiol (1993) 264(2 Pt 2):F292-F299.
37. Derubertis FR, Craven PA: Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes (1994) 43(1):1-8.
38. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, Narumiya S: cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem (1994) 269(13):9986-9992.
39. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M: Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem (1994) 269(16):12173-12178.
40. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A et al.: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 388(6643):678-682.
41. Komhoff M, Lesener B, Nakao K, Seyberth HW, Nusing RM: Localization of the prostacyclin receptor in human kidney. Kidney Int (1998) 54(6):1899-1908.
42. Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A, Narumiya S: In situ hybridization studies on prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol (1995) 116(7):2828-2837.
43. Schnermann J: Cyclooxygenase-2 and macula densa control of renin secretion. Nephrol Dial Transplant (2001) 16(9):1735-1738. This paper describes the glomerular effects of COX2 inhibitors
44. 2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukot Essent Fatty Acids (2001) 65(4):223-227.
45. Pallone TL, Silldorff EP, Turner MR: Intrarenal blood flow: Microvascular anatomy and the regulation of medullary perfusion. Clin Exp Pharmacol Physiol (1998) 25(6):383-392.
46. 2 receptors in the rabbit renal preglomerular microvasculature. Biochim Biophys Acta (1990) 1053(2):156-161.
47. Patrono C, Pugliese F, Ciabattoni G, Patrignani P, Maseri A, Chierchia S, Peskar BA, Cinotti GA, Simonetti BM, Pierucci A: Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest (1982) 69(1):231-239.
48. Ito S, Carretero OA, Abe K, Beierwaltes WH, Yoshinaga K: Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int (1989) 35(5):1138-1144.
49. Beierwaltes WH, Schryver S, Sanders E, Strand J, Romero JC: Renin release selectively stimulated by prostaglandin I2 in isolated rat glomeruli. Am J Physiol (1982) 243(3):F276-F283.
50. Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, Tago K, Irie K, Muraki T, Demura H, Zardi L: Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis (1999) 145(2):333-340.
51. Nasrallah R, Zimpelmann J, Singh S, Hebert RL: Molecular and biochemical characterization of prostacyclin receptors in rat kidney. Am J Physiol Renal Physiol (2001) 280(2):F266-F277.
52. 2/IP system in cortical collecting duct. Am J Physiol Renal Physiol (2000) 283(4):F689-F698.
53. Hebert RL, O'Connor T, Neville C, Burns KD, Laneuville O, Peterson LN: Prostanoid signaling, localization, and expression of IP receptors in rat thick ascending limb cells. Am J Physiol (1998) 275(6 Pt 2):F904-F914.
54. Hebert RL, Regnier L, Peterson LN: Rabbit cortical collecting ducts express a novel prostacyclin receptor. Am J Physiol (1995) 268(1 Pt 2):F145-F154.
55. Oida H, Hirata M, Sugimoto Y, Ushikubi F, Ohishi H, Mizuno N, Ichikawa A, Narumiya S: Expression of messenger RNA for the prostaglandin D receptor in the leptomeninges of the mouse brain. FEBS Lett (1997) 417(1):53-56.
56. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M: Molecular cloning and characterization of the human prostanois DP receptor. J Biol Chem (1995) 270(32):18910-18916.
57. Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S: Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA (1994) 91(23):11192-11196.
58. 2 on hemodynamics, renal function, and blood gas analyses. Am J Obstet Gynecol (1987) 156(4):843-851.
59. Nowak J, Wennmalm A: Human forearm and kidney conversion of arachidonic acid to prostaglandins. Acta Physiol Scand (1979) 106(3):307-312.
60. 2 prostanoid receptor subtypes. Eur J Pharmacol (1997) 340(2-3):227-241.
61. Schaefer M, Hofmann T, Schultz G, Gudermann T: A new prostaglandin E receptor mediates calcium influx and acrosome reaction in human spermatozoa. Proc Natl Acad Sci USA (1998) 95(6):3008-3013.
62. Toh H, Ichikawa A, Narumiya S: Molecular evolution of receptors for eicosanoids. FEBS Lett (1995) 361(1):17-21.
63. Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE, Fairbairn CE, Kedzie KM, Woodward DF, Gil DW: Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol (1994) 46(2):213-220.
64. 2 receptor EP2 subtype. J Biol Chem (1994) 269(16):11873-11877.
65. Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, Matsuoka T, Noda Y, Tanaka T, Yoshida N, Narumiya S et al: Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. Proc Natl Acad Sci USA (1999) 96(18):10501-10506.
66. Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglafndin EP2 receptor. BMC Pharmacol (2000) 2(1):14.
67. Ono's new drugs R&D pipeline. Pharma Jpn (1999) 1675:16.
68. 2 EP2 and EP4 receptors in the rat kidney. Am J Physiol Renal Physiol (2001) 280(6):F1001-F1009.
69. Breyer MD, Davis L, Jacobson HR, Breyer RM: Differential localization of prostaglandin E receptor subtypes in human kidney. Am J Physiol (1996) 270(5 Pt 2):F912-F918.
70. Kennedy C, Schneider A, Young-Siegler A, Brandon S, Breyer M, Breyer R: Regulation of renin and aldosterone levels in mice lacking the prostaglandin EP2 receptor. J Am Soc Nephrol (1999) 10:348A.
71. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell (1997) 91(2):197-208.
72. Cheng HF, Wang SW, Zhang MZ, McKanna JA, Breyer R, Harris RC: Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1. Am J Physiol Regul Integr Comp Physiol (2002) 283(3):R638-R646.
73. Kennedy CRJ, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, Breyer RM: Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med (1999) 5(2):217-220.
74. 2receptors. Hypertension (2000) 35(5):1129-1134.
75. Breyer RM, Davis LS, Nian C, Redha R, Stillman B, Jacobson HR, Breyer MD: Cloning and expression of the rabbit prostaglandin EP4 receptor. Am J Physiol (1996) 270(3 Pt 2):F485-F493.
76. 2. Mol Pharmacol (2001) 60(1):36-41.
77. Sugimoto Y, Narumiya S, Ichikawa A: Distribution and function of prostanoid receptors: Studies from knockout mice. Prog Lipid Res (2000) 39(4):289-314.
78. Bek M, Nusing R, Kowark P, Henger A, Mundel P, Pavenstadt H: Characterization of prostanoid receptors in podocytes. J Am Soc Nephrol (1999) 10(10):2084-2093.
79. 2 protects gastric mucosal cells from apoptosis va EP2 and EP4 receptor activation. J Biol Chem (2003) 278(15):12752-12758.
80. Silverstein FE: Improving the gastrointestinal safety of NSAIDs: The development of misoprostol - From hypothesis to clinical practice. Dig Dis Sci (1998) 43(3):447-458.
81. Jensen BL, Schmid C, Kurtz A: Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol (1996) 271 (3 Pt 2):F659-F669.
82. Tan SY, Shapiro R, Franco R, Stockard H, Mulrow PJ: Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med (1979) 90(5):783-785.
83. 2-induced hypertension in conscious dogs. Am J Physiol (1979) 237(4):H449-H454.
84. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med (1984) 310(9):563-572.
85. Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition. Am J Med (1999) 107(6A):S65-S70, discussion 70S-71S.
86. Perazella MA, Tray K: Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med (2001) 111(1):64-67.
87. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf (2002) 25(7):537-544.
88. Ichihara A, Imig JD, Inscho EW, Navar LG: Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: Interaction with neuronal NOS. Am J Physiol (1998) 275(4 Pt 2):F605-F612.
89. Watabe S, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, Ito S, Narumiya S, Ichikawa A: Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem (1993) 268(27):20175-20178.
90. Båtschake B, Nilsson C, Sundelin J: Molecular characterization of the mouse prostanoid EP1 receptor gene. Eur J Biochem (1995) 231(3):809-814.
91. Funk CD, Furci L, FitzGerald GA, Grygorczyk R, Rochette C, Bayne MA, Abramovitz M, Adam M, Metters KM: Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem (1993) 268(35):26767-26772.
92. 2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest (2001) 107(3):325-331.
93. Malmberg AB, Rafferty MF, Yaksh TL: Antinociceptive effect of spinally delivered prostaglandin E receptor antagonists in the formalin test on the rat. Neurosci Lett (1994) 173(1-2):193-196.
94. Zhang Z, Hefferan MP, Loomis CW: Topical bicuculline to the rat spinal cord induces highly localized allodynia that is mediated by spinal prostaglandins. Pain (2001) 92(3):351-361.
95. 2 in rat supraoptic neurones. J Neuroendocrinol (2002) 14(1):64-72.
96. 2 antagonist, and its analogs. J Med Chem (1996) 39(2):609-613.
97. 2 antagonist and analgesic. Bioorg Med Chem Lett (1994) 4(3):509-514.
98. Ono Pharmaceutical Co Ltd: Annual Report 1999 - Ono Pharmaceuticals. Annual Report (1999) March 31.
99. Sugimoto Y, Namba T, Shigemoto R, Negishi M, Ichikawa A, Narumiya S: Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. Am J Physiol (1994) 266(5 Pt 2):F823-F828.
100. + absorption by activating the EP1 receptor. J Clin Invest (1998) 102(1):194-201.
101. 2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest (1991) 87(6):1992-1998.
102. 2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol (1990) 259(2 Pt 2):F318-F325.
103. Ishibashi R, Tanaka I, Kotani M, Muro S, Goto M, Sugawara A, Mukoyama M, Sugimoto Y, Ichikawa A, Narumiya S, Nakao K: Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int (1999) 56(2):589-600.
104. Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P: Prostanoids and their receptors. In: Comprehensive Medicinal Chemistry. Emmet JC (ed), Oxford Pergamon Press, Oxford, UK (1990):643-714.
105. Makino H, Tanaka I, Mukoyama M, Sugawara A, Mori K, Muro S, Suganami T, Yahata K, Ishibashi R, Ohuchida S, Maruyama T et al: Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol (2002) 13(7):1757-1765.
106. 2 receptor. J Biol Chem (1994) 269(8):6163-6169.
107. Kotani M, Tanaka I, Ogawa Y, Usui T, Mori K, Ichikawa A, Narumiya S, Yoshimi T, Nakao K: Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: Multiple second messenger systems and tissue-specific distributions. Mol Pharmacol (1995) 48(5):869-879.
108. Irie A, Sugimoto Y, Namba T, Harazono A, Honda A, Watabe A, Negishi M, Narumiya S, Ichikawa A: Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem (1993) 217(1):313-318.
109. Juteau H, Gareau Y, Labelle M, Lamontagne S, Tremblay N, Carriere MC, Sawyer N, Denis D, Metters KM: Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry. Bioorg Med Chem Lett (2001) 11(5):747-749.
110. Juteau H, Gareau Y, Labelle M, Sturino CF, Sawyer N, Tremblay N, Lamontagne S, Carriere MC, Denis D, Metters KM: Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg Med Chem (2001) 9(8):1977-1984.
111. Namba T, Sugimoto Y, Negishi M, Irie A, Ushikubi F, Kakizuka A, Ito S, Ichikawa A, Narumiya S: Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature (1993) 365(6442):166-170.
112. Hasegawa H, Negishi M, Ichikawa A: Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity. J Biol Chem (1996) 271(4):1857-1860.
113. Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, Tanaka T et al: Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature (1998) 395(6699):281-284.
114. 2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest (2001) 107(5):603-610.
115. Regan JW, Bailey TJ, Donello JE, Pierce KL, Pepperl DJ, Zhang D, Kedzie KM, Fairbairn CE, Bogardus AM, Woodward DR et al: Molecular cloning and expression of human EP3 receptors: Evidence of three variants with differing carboxyl termini. Br J Pharmacol (1994) 112(2):377-385.
116. Kunapuli SP, Fen Mao G, Bastepe M, Liu-Chen LY, Li S, Cheung PP, DeRiel JK, Ashby B: Cloning and expression of a prostaglandin E receptor EP3 subtype from human erythroleukaemia cells. Biochem J (1994) 298(2):263-267.
117. Sugimoto Y, Namba T, Honda A, Hayashi Y, Negishi M, Ichikawa A, Narumiya S: Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem (1992) 267(10):6463-6466.
118. Breyer MD, Jacobson HR, Davis LS, Breyer RM: In situ hybridization and localization of mRNA for the rabbit prostaglandin EP3 receptor. Kidney Int (1993) 44(6):1372-1378.
119. 2 binding sites in rat kidney. Acta Physiol Scand (1990) 139(3):405-415.
120. 2 binding sites in human renal tissue: Characterization and localization by radioligand binding and autoradiography. Acta Physiol Scand (1990) 139(3):393-404.
121. 2 receptor mRNA along mouse nephron segments by RT-PCR. Am J Physiol (1994) 266(5 Pt 1):C1453-C1458.
122. 1 on the permeability response of the isolated collecting tubule to vasopressin, adenosine 3′,5′-monophosphate, and theophylline. J Clin Invest (1968) 47(5):1154-1161.
123. 2 receptors modulate water and sodium transport in rabbit cortical collecting duct. Am J Physiol (1993) 265(5 Pt 2):F643-F650.
124. Sonnenburg WK, Zhu JH, Smith WL: A prostaglandin E receptor coupled to a pertussis toxin-sensitive guanine nucleotide regulatory protein in rabbit cortical collecting tubule cells. J Biol Chem (1990) 265(15):8479-8483.
125. 2 on chloride transport across the rabbit thick ascending limb of Henle. Selective inhibitors of the medullary portion. J Clin Invest (1979) 64(2):495-502.
126. 2 and G-proteins in rat medullary thick ascending limb. Am J Physiol (1996) 270(5 Pt 2):F711-F717.
127. 2. Am J Physiol (1998) 275(6 Pt 2):F955-F961.
128. Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R: Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem (1994) 269(4):2632-2636.
129. Woodward DF, Fairbairn CE, Lawrence RA: Identification of the FP-receptor as a discrete entity by radioligand binding in biosystems that exhibit different functional rank orders of potency in response to prostanoids. Adv Exp Med Biol (1997) 400A:223-227.
130. Griffin BW, Williams GW, Crider JY, Sharif NA: FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study. J Pharmacol Exp Ther (1997) 281(2):845-854.
131. Pierce KL, Bailey TJ, Hoyer PB, Gil DW, Woodward DF, Regan JW: Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J Biol Chem (1997) 272(2):883-887.
132. Sugimoto Y, Hasumoto K, Namba T, Irie A, Katsuyama M, Negishi M, Kakizuka A, Naumiya S, Ichikawa A: Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem (1994) 269(2):1356-1360.
133. 2α receptors in birth.
134. Hasumoto K, Sugimoto Y, Gotoh M, Segi E, Yamasaki A, Yamaguchi M, Honda H, Hirai H, Negishi M, Kakizuka A, Ichikawa A: Characterization of the mouse prostaglandin F receptor gene: A transgenic mouse study of a regulatory region that controls its expression in the stomach and kidney but not in the ovary. Genes Cells (1997) 2(9):571-580.
135. 2 and proliferator activation receptor-γ agonists. J Immunol (2000) 164(3):1498-1504.
136. Shimizu T, Yoshitomi K, Nakmura M, Imai M: Site and mechanism of action of trichlormethiazide in rabbit distal nephron segments perfused in vitro. J Clin Invest (1988) 82(2):721-730.
137. Hoenderop JG, Willems PH, Bindels RJ: Toward a comprehensive molecular model of active calcium reabsorption. Am J Physiol Renal Physiol (2000) 278(3):F352-F360.
138. Morgan LJ, Liebman M, Broughton KS: Caffeine-induced hypercalciuria and renal prostaglandins: Effect of aspirin and n-3 polyunsaturated fatty acids. Am J Clin Nutr (1994) 60(3):362-368.
139. Crawford ML, Waller PC, Wood SM: Severe cystitis associated with tiaprofenic acid. Br J Urol (1997) 79(4):578-584.
140. Kelly JD, Young MR, Johnston SR, Keane PF: Clinical response to an oral prostaglandin analogue in patients with interstitial cystitis. Eur Urol (1998) 34(1):53-56.
141. Klarskov P: Influence of prostaglandins and ketoprofen on contractile responses of human and pig detrusor and trigone muscles in vitro. Pharmacol Toxicol (1987) 61(1):37-41.
142. Zwergel U, Zwergel T, Leis HJ, Gleispach H, Alexandridis T, Belletz M, Kirsten R: Eicosanoid synthesis in the isolated human renal pelvis, ureter and bladder. Br J Urol (1991) 67(3):246-250.
143. Poli E, Macaluso G, Pozzoli C: Actions of two novel prostaglandin analogs, SC-29169 and SC-31391, on guinea pig and human isolated urinary bladder. Gen Pharmacol (1992) 23(5):805-809.
144. 2α and prostacyclin on vesicourethral smooth muscle. J Urol (1986) 135(2):431-437.
145. Park JM: Role of prostaglandin in bladder smooth muscle cell gene expression. Urology (2001) 57(6 Suppl 1):105.
146. Ueda S, Yoshida M, Yano S, Mutoh S, Ikegami K, Sakanashi M: Comparison of the effects of primary prostaglandin on isolated human urinary bladder. J Urol (1985) 133(1):114-116.
147. Saito O, Guan Y, Qi Z, Davis LS, Komhoff M, Sugimoto Y, Narumiya S, Breyer RM, Breyer MD: Expression of the prostaglandin F receptor (FP) gene along the mouse genitourinary tract. Am J Physiol Renal Physiol (2003) 284(6):F1164-F1170.
148. Andersson KE: Bladder activation: Afferent mechanisms. Urology (2002) 59(5 Suppl 1):43-50.
149. Miura A, Kawatani M, Maruyama T, De Groat WC: Effect of prostaglandins on parasympathetic neurons in the rat lumbosacral spinal cord. Neuroreport (2002) 13(12):1557-1562.
150. 2. Eur J Neurosci (1999) 11(6):1849-1856.
151. Nakamura K, Kaneko T, Yamashita Y, Hasegawa H, Katoh H, Negishi M: Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous system. J Comp Neurol (2000) 421(4):543-569.
152. Sugimoto Y, Shigemoto R, Namba T, Negishi M, Mizuno N, Narumiya S, Ichikawa A: Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system. Neuroscience (1994) 62(3):919-928.
153. Von Euler US: On the specific vasodilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol (1936) 88:213-234.
154. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS, Wheeler TM, Breyer MD et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 3(4):287-303.
155. 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer (2000) 82(12):2000-2006.
156. 2α regulation of LH action on testicular testosterone production. Adv Prostaglandin Thromboxane Res (1980) 8:1313-1315.
157. 2 stimulate testosterone production by goldfish testis in vitro. Gen Comp Endocrinol (1993) 90(1):109-118.
158. 2 production in rat vas deferens. Endocrinology (1986) 119(4):1733-1740.
159. McKanna JA, Zhang MZ, Wang JL, Cheng H, Harris RC: Constitutive expression of cyclooxygenase-2 in rat vas deferens. Am J Physiol (1998) 275(1 Pt 2):R227-R233.
160. 2 receptor subtype EP2 gene expression in the mouse uterus coincides with differentiation of the luminal epithelium for implantation. Endocrinology (1997) 138(11):4599-4606.
161. Lim H, Ma L, Ma WG, Maas RL, Dey SK: Hoxa-10 regulates uterine stromal cell responsiveness to progesterone during implantation and decidualization in the mouse. Mol Endocrinol (1999) 13(6):1005-1017.
162. Katsuyama M, Sugimoto Y, Morimoto K, Hasumoto K, Fukumoto M, Negishi M, Ichikawa A: 'Distinct cellular localization' of the messenger ribonucleic acid for prostaglandin E receptor subtypes in the mouse uterus during pseudopregnancy. Endocrinology (1997) 138(1):344-350.
163. Segi E, Haraguchi K, Sugimoto Y, Tsuji M, Tsunekawa H, Tamba S, Tsuboi K, Tanaka S, Ichikawa A: Expression of messenger RNA for prostaglandin E receptor subtypes EP4/EP2 and cyclooxygenase isozymes in mouse periovulatory follicles and oviducts during superovulation. Biol Reprod (2003) 68(3):804-811.
164. 2α receptor in the rat myometrium during pregnancy and labor. Am J Obstet Gynecol (2000) 182(4):919-925.
165. Ma X, Wu WX, Nathanielsz PW: Differential regulation of prostaglandin EP and EP receptors in pregnant sheep myometrium and endometrium during spontaneous term labor. Biol Reprod (1999) 61(5):1281-1286.
166. Marpeau L, Percque M, Larue L, Guettier X, Jault T, Pigne A, Barrat J: Intravenous sulprostone and uterine scarring based upon 22 cases of therapeutic abortion during 2nd and 3rd trimesters of pregnancy. Eur J Obstet Gynecol Reprod Biol (1993) 50(2):105-108.
167. Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu EE, Ulmann A: Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience. N Engl J Med (1990) 322(10):645-648.
168. De Boer MA, Van Gemund N, Scherjon SA, Kanhai HH: Low dose sulprostone for termination of second and third trimester pregnancies. Eur J Obstet Gynecol Reprod Biol (2001) 99(2):244-248.
169. 2 receptors EP2 and EP4 in human ovarian granulosa-luteal cells. J Clin Endocrinol Metab (2001) 86(4):1765-1768.
170. 2 receptor. J Clin Invest (1999) 103(11):1539-1545.
171. 2α receptor in ovine corpora lutea. Eur J Biochem (1974) 41(1):103-107.
172. 2α receptor in human corpora lutea. Lancet (1974) 1(7866):1120.
173. 2α receptor with luteal cell apoptosis in ovaries of pseudopregnant mice. J Reprod Fertil (1997) 109(1):45-51.
174. 2α based on serial biopsies in vivo. Reproduction (2001) 121(6):905-913.